Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Vincent

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survivalGregory M M Videtic, Larry W Stitt, A Rashid Dar, et al.
International Journal of Cancer|June 20, 2024
Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancerBarbara Melosky, Mark D Vincent, Anna L McGuire, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2022
Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot studyDaniel A Breadner, Mark D Vincent, Rohann Correa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJean-Yves Douillard, Paulo M Hoff, Jamey R Skillings, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung CancerBeatrice T B Preti, Michael S Sanatani, Daniel Breadner, et al.
Canadian Respiratory Journal|August 19, 2005
Does sex influence the impact that smoking, treatment interruption and impaired pulmonary function have on outcomes in limited stage small cell lung cancer treatment?Gregory M M Videtic, Pauline T Truong, Robert B Ash, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.
Future Oncology (London, England)|January 4, 2017
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancerMark D Vincent, Daniel Breadner, Denis Soulieres, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2012
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II ConsortiumNicholas P Campbell, Rangesh Kunnavakkam, Natasha Leighl, et al.
Thoracic Cancer|May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trialRichard A Malthaner, Edward Yu, Michael Sanatani, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2003
Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survivalGregory M M Videtic, Larry W Stitt, A Rashid Dar, et al.
International Journal of Cancer|June 20, 2024
Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancerBarbara Melosky, Mark D Vincent, Anna L McGuire, et al.
Lung Cancer (Amsterdam, Netherlands)|February 6, 2022
Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot studyDaniel A Breadner, Mark D Vincent, Rohann Correa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2002
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJean-Yves Douillard, Paulo M Hoff, Jamey R Skillings, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung CancerBeatrice T B Preti, Michael S Sanatani, Daniel Breadner, et al.
Canadian Respiratory Journal|August 19, 2005
Does sex influence the impact that smoking, treatment interruption and impaired pulmonary function have on outcomes in limited stage small cell lung cancer treatment?Gregory M M Videtic, Pauline T Truong, Robert B Ash, et al.
Lung Cancer (Amsterdam, Netherlands)|September 18, 2025
Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLCBarbara Melosky, Quincy S C Chu, Rosalyn A Juergens, et al.
Future Oncology (London, England)|January 4, 2017
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancerMark D Vincent, Daniel Breadner, Denis Soulieres, et al.
Lung Cancer (Amsterdam, Netherlands)|July 27, 2012
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II ConsortiumNicholas P Campbell, Rangesh Kunnavakkam, Natasha Leighl, et al.
Thoracic Cancer|May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trialRichard A Malthaner, Edward Yu, Michael Sanatani, et al.
Pageof 4